视网膜新生血管中的小胶质细胞极化:敌友之争?(英文)

徐雯鑫 ,  韦俏燕 ,  周顺 ,  彭澳华 ,  丁纯

中南大学学报(医学版) ›› 2026, Vol. 51 ›› Issue (3) : 544 -568.

PDF (2384KB)
中南大学学报(医学版) ›› 2026, Vol. 51 ›› Issue (3) : 544 -568. DOI: 10.11817/j.issn.1672-7347.2026.250627
综述

视网膜新生血管中的小胶质细胞极化:敌友之争?(英文)

作者信息 +

Microglial polarization in retinal neovascularization: Friend or foe?

Author information +
文章历史 +
PDF (2440K)

摘要

视网膜新生血管(retinal neovascularization,RNV)的形成是缺血性视网膜病变(如早产儿视网膜病变、增殖性糖尿病视网膜病变)致盲的核心病理过程。现有抗血管内皮生长因子(vascular endothelial growth factor,VEGF)治疗存在应答不全、注射负担重等问题,因此阐明RNV的新调控机制具有重要意义。小胶质细胞作为视网膜常驻免疫细胞,其功能极化在RNV中发挥关键但复杂的调控作用。多数研究表明,促炎相关的M1型极化通过分泌VEGF、肿瘤坏死因子α(tumor necrosis factor alpha,TNF-α)、白细胞介素-1β(interleukin-1 beta,IL-1β)等因子,加剧血管渗漏和病理性新生血管簇形成;而修复型M2型极化则与促进血管修复及稳态重建相关。然而,借助单细胞转录组学等新技术,研究发现小胶质细胞在RNV微环境中存在显著的表型异质性,超越了经典的M1/M2二分法。新近证据亦揭示M2样表型并非始终具有保护作用,在特定病理条件(如慢性缺氧、氧化应激)下,其可发挥促纤维化或异常血管重塑作用,提示小胶质细胞极化方向的功能结局高度取决于微环境。因此,未来的治疗策略不应简单追求改变小胶质细胞的极化表型,而应靶向调控关键信号通路和功能模块,从而将RNV中的破坏性炎症环境重塑为有利于血管修复的治疗性环境。这将为视网膜血管疾病的精准干预提供理论依据。

Abstract

Retinal neovascularization (RNV) is the central pathological process leading to blindness in ischemic retinal diseases, such as retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR). Current anti-vascular endothelial growth factor (VEGF) therapies are limited by incomplete responses and substantial injection burdens, highlighting the importance of elucidating novel regulatory mechanisms underlying RNV. As resident immune cells of the retina, microglia play critical yet complex regulatory roles in RNV through functional polarization. Most studies suggest that pro‑inflammatory M1‑like polarization aggravates vascular leakage and pathological neovascular tuft formation by secreting factors such as VEGF, tumor necrosis factor-alpha (TNF‑α), and interleukin-1 beta (IL‑1β). In contrast, reparative M2‑like polarization has been associated with vascular repair and restoration of tissue homeostasis. However, with the application of emerging technologies such as single‑cell transcriptomics, increasing evidence has revealed substantial phenotypic heterogeneity of microglia within the RNV microenvironment, extending beyond the classical M1/M2 dichotomy. Recent findings further indicate that M2-like phenotypes are not invariably protective. Under specific pathological conditions, including chronic hypoxia and oxidative stress, M2-like microglia may promote fibrosis and aberrant vascular remodeling, suggesting that the functional consequences of microglial polarization are highly dependent on the surrounding microenvironment. Therefore, future therapeutic strategies should not simply aim to alter microglial polarization states, but rather selectively target key signaling pathways and functional modules to transform the destructive inflammatory milieu in RNV into a therapeutic environment conducive to vascular repair. Such approaches may provide a theoretical basis for precision interventions in retinal vascular diseases.

Graphical abstract

关键词

视网膜新生血管 / 缺血性视网膜病变 / 小胶质细胞 / 血管内皮生长因子 / 极化 / 神经血管单元

Key words

retinal neovascularization / ischemic retinal diseases / microglia / vascular endothelial growth factor / polarization / neurovascular unit

引用本文

引用格式 ▾
徐雯鑫,韦俏燕,周顺,彭澳华,丁纯. 视网膜新生血管中的小胶质细胞极化:敌友之争?(英文)[J]. 中南大学学报(医学版), 2026, 51(3): 544-568 DOI:10.11817/j.issn.1672-7347.2026.250627

登录浏览全文

4963

注册一个新账户 忘记密码

Retinal neovascularization (RNV) is a hallmark pathological feature of ischemic retinopathies including proliferative diabetic retinopathy (PDR), retinopathy of prematurity (ROP), and neovascular age-related macular degeneration (AMD)[1]. Approximately 30% of diabetic retinopathy (DR) patients ultimately develop PDR, wherein RNV-mediated vitreous hemorrhage and tractional retinal detachment emerge as the predominant contributors to irreversible visual impairment[2]. Notably, ROP develops in 15% to 20% of very low birth weight (VLBW) infants, with hypoxia-induced pathological RNV constituting its defining characteristic[3].
While the exact molecular pathogenesis of RNV requires further elucidation, prevailing evidence establishes hypoxia-mediated activation of hypoxia-inducible factor-1α (HIF-1α) as the predominant pathogenic cascade. This molecular switch triggers a dramatic 10- to 20-fold overexpression of vascular endothelial growth factor (VEGF), culminating in the development of structurally compromised, hyperpermeable vasculature that severely impairs blood-retinal barrier (BRB) function[2, 4]. Three principal pathogenic pathways converge in RNV development: 1) VEGF/VEGF receptor 2 (VEGFR2)-mediated endothelial cell proliferation[5], 2) inflammation from macrophages and microglia secreting interleukin (IL)-6 and tumor necrosis factor-α (TNF-α)[6-7], and 3) cell cycle dysregulation through cyclin D1 overexpression coupled with platelet-derived growth factor (PDGF)-dependent pericyte depletion[8]. The current therapeutic paradigm for RNV predominantly relies on intravitreal anti-VEGF agents (e.g., ranibizumab) and panretinal photocoagulation (PRP), both of which present considerable clinical constraints. Notably, intravitreal anti-VEGF monotherapy yields incomplete efficacy, with approximately 30% of patients demonstrating either suboptimal response or acquired drug resistance―a therapeutic limitation exacerbated by the requisite frequent administration regimen (typically 6 to 8 intravitreal injections annually) that elevates both infection risk and treatment-associated economic burden[9-10]. While PRP achieves suppression of neovascularization through selective retinal photocoagulation, this intervention consistently induces irreversible paracentral visual field defects and persistent dark adaptation impairment[11-12]. These persistent clinical shortcomings underscore the pressing need for the development of advanced sustained-release drug delivery platforms and mechanistically distinct therapeutic approaches targeting pathological ocular angiogenesis.
Microglia, the resident immune sentinels of the retina and central nervous system (CNS), exhibit a dual role in retinal homeostasis and pathology through their dynamic interactions with neural and vascular components[13-14]. These multifunctional cells contribute to essential physiological processes, including vascular remodeling, synaptic pruning, and immune surveillance, via continuous crosstalk with neurons, blood vessels, and glial cells[7]. Their functional dichotomy is particularly striking: While they maintain tissue homeostasis by phagocytosing cellular debris, they can also trigger neuroinflammatory cascades through cytokine release[15]. Microglia exhibit remarkable phenotypic plasticity, undergoing distinct polarization patterns in response to diverse microenvironmental stimuli, a process that subsequently determines their functional outcomes in retinal pathophysiology. The traditional M1/M2 polarization framework categorizes their activation states—pro-inflammatory M1 microglia exacerbate retinal damage via IL-6 and IL-8 secretion, whereas anti-inflammatory M2 phenotypes facilitate tissue repair through IL-10 and other protective mediators[16-17]. However, a recent single-cell transcriptomic study[18] has revolutionized our understanding, revealing a spectrum of activation states beyond this binary classification.
A recent study[7] has identified retinal microglia as critical components of the neurovascular unit (NVU), playing essential roles in retinal vascular development and in dynamic interactions with vascular endothelial cells and neuronal synapses to regulate retinal vascular homeostasis under pathological conditions. The analysis of multiplex immunofluorescence spatial imaging experiments has revealed significant spatial associations between microglia and pathological RNV in oxygen-induced retinopathy (OIR) models[19]. Notably, microglial polarization determines their dual regulatory effects on RNV progression: M1-polarized microglia exacerbate inflammation via pathways such as the absent in melanoma 2 (AIM2)/apoptosis-associated speck-like protein containing a CARD (ASC)/caspase-1 (CASP1)/IL-1β signaling pathway[20-21]. Conversely, M2 polarization exerts anti-angiogenic effects through the thrombospondin-1 (TSP-1)/microRNA-27a-5p (miR-27a-5p)/Smad3 axis, with M2-derived exosomes mitigating pericyte apoptosis and promoting vascular stabilization[22]. These groundbreaking discoveries provide novel mechanistic insights into how microglial polarization modulates RNV through interconnected inflammatory and angiogenic networks. Consequently, precise modulation of microglial polarization has emerged as a key therapeutic strategy for neovascular retinal diseases, with several targeted interventions currently under preclinical investigation.
Recent advances in single-cell sequencing and metabolomics have highlighted the intricate relationship between microglial polarization and RNV. However, current research remains fragmented across various pathological stimuli, lacking systematic integration of the underlying molecular mechanisms and therapeutic potential. This review provides a comprehensive analysis of the dual roles of microglial polarization in RNV, advancing beyond the conventional M1/M2 dichotomy. Leveraging advanced single-cell sequencing technologies, we aim to systematically elucidate how non-classical polarization phenotypes exert precise regulatory control over RNV. Through a multidimensional analytical approach, we discuss these mechanisms and explore therapeutic strategies targeting microglial polarization, thereby proposing novel treatment avenues for retinal neovascular diseases.

1 Retinal vasculature

1.1 Anatomical structure and physiological roles of the retinal vasculature

As an extension of the CNS, the retina possesses a specialized vascular system to meet its high metabolic demands (Supplementary Figure 1, https://doi.org/10. 57760/sciencedb.xbyxb.00106). The retinal blood supply features a dual circulatory system: the central retinal artery nourishes the inner layers (from the ganglion cell layer to the inner nuclear layer), while the choriocapillaris supports the outer layers (from the outer nuclear layer to the photoreceptor layer) via diffusion[23-24]. The central retinal artery branches into arterioles that give rise to 3 distinct capillary networks: The superficial capillary plexus (SCP), intermediate capillary plexus (ICP), and deep capillary plexus (DCP). Together, these vascular plexuses form a sophisticated three-dimensional oxygen delivery architecture[24].

The retina possesses a complete BRB, which consists of inner and outer components. The inner blood-retinal barrier (iBRB) is primarily formed by retinal capillary endothelial cells connected by tight junctions, with pericytes and the endfeet of Müller glial cells playing critical supporting roles in its induction and maintenance[25-26]. The outer blood-retinal barrier is composed of retinal pigment epithelium (RPE) and its tight junction complexes, which mediate selective molecular transport between the retina and choroid via polarized transport systems[25].

1.2 NVU of the retina

The NVU concept, which was initially introduced to characterize functional neuron-glia-vessel interactions in the brain, has been subsequently extended to retinal studies[27]. The retinal NVU, where diverse cellular components are intricately interconnected through complex molecular signaling networks, has emerged as a pivotal focus in ophthalmic research. The retinal NVU comprises endothelial cells, pericytes, Müller cells, astrocytes, microglia/macrophages, and neurons, forming an intricate 3-dimensional (3D) network[28-29] (Supplementary Figure 2, https://doi.org/10.57760/sciencedb. xbyxb.00106). The retina relies on NVU mechanisms to preserve microenvironmental homeostasis via structural and functional adaptations. Functionally, specialized neurovascular coupling facilitates rapid hemodynamic regulation, with retinal blood flow responses exceeding cerebral counterparts by 30% to 40%[7, 30].

The NVU comprises a sophisticated regulatory network established through orchestrated interactions and multifaceted signaling among its cellular constituents. Endothelial cells and neurons collectively regulate microvascular tone through bidirectional signaling[31]. This coordinated activity is complemented by astrocytes, which structurally interface with vascular smooth muscle cells via their endfeet and mediate neurovascular coupling through mechanisms involving calcium transients and serotonergic synaptic transmission[32]. Furthermore, pericytes contribute to cerebrovascular homeostasis by modulating cerebral small vessel disease progression via molecular interactions with transient receptor potential vanilloid 4 (TRPV4) channels[33]. Under pathological conditions, however, this cellular synergy can be disrupted by events such as JNK pathway activation[34]. Importantly, the system’s dynamic equilibrium is maintained through responsive adaptations to bioactive compounds[35]. Additionally, microglia make essential contributions to this regulatory network. Under physiological conditions, microglia sustain homeostasis via P2Y12 purinergic receptor (P2Y12R)-mediated synaptic pruning, whereas their activated state triggers IL-1β secretion, elevating pericyte contractility by 300%[36]. Recent therapeutic advances demonstrate that M2-polarized microglia enhance vascular repair through exosomal miR-124-3p transfer, which suppresses pericyte apoptosis[22].

1.3 Physiological and pathological characteristics of retinal vessels

Retinal vascular biology encompasses 3 principal adaptive responses to microenvironmental alterations: Physiological repair/reperfusion, pathological neovascu-larization, and vascular stabilization/maturation. While these processes share a dependence on canonical molecular pathways like VEGF signaling and hypoxia response, as well as functional crosstalk among endothelial cells, pericytes, and immune components, their etiological drivers and phenotypic outcomes diverge substantially[29, 37]. Physiological repair constitutes a confined, spatially organized reaction to ischemic insult, directed toward reestablishing perfusion and barrier competence[38]. In contrast, pathological neovascularization arises from persistent inflammatory and hypoxic stimuli, yielding architecturally disorganized, hyperpermeable vascular networks[39]. Vascular stabilization and maturation denote the functional terminus of both trajectories, defined by consolidated pericyte ensheathment and reconstituted barrier integrity[40].

Physiological vasculature exhibits complete pericyte coverage, regular branching patterns, and stable metabolic coupling[30], all of which rely on key molecules such as ATPase H+ transporting accessory protein 2 (ATP6AP2) for endothelial migration and tip cell polarity maintenance[41], while the suppressor of cytokine signaling 3 (SOCS3)-signal transducer and activator of transcription 3 (STAT3) axis fine-tunes angiogenesis via myeloid cell regulation[42]. Disruption of retinal microenvironmental homeostasis initiates a cascade of pathological events, with pathological neovascularization emerging as a hallmark feature shared by multiple blinding eye diseases. The core driver of this process is hypoxia, which stabilizes the accumulation of HIF-1α, subsequently upregulating key hypoxia-responsive factors including VEGF[43-44]. Notably, different types of ischemic insults trigger characteristic pathological responses: Under conditions of vascular occlusion-induced ischemia, functional deficiency of endothelial NADPH oxidase 4 (NOX4) significantly impairs vascular regenerative capacity[45], while concurrent excessive mitochondrial fission promotes pathological angiogenesis[46]. Of particular importance is the complex bidirectional regulatory relationship between inflammatory responses and pathological angiogenesis. In PDR, sustained inflammatory microenvironments not only directly promote neovascular growth but may also contribute to anti-VEGF treatment resistance through multiple mechanisms[47]. Physiological and pathological retinal vasculature exhibit distinct molecular signatures and morphofunctional characteristics. Physiological vessels maintain stable pericyte-endothelial coupling and organized branching patterns[48], while pathological vessels are characterized by hyperproliferative endothelia, increased vascular permeability, and disorganized networks[48-49]. Metabolically, myeloid cells (including macrophages and microglia) surrounding pathological vessels shift to a hyperglycolytic state, establishing a pro-angiogenic niche[50]. Therapeutically, these differences are clinically relevant: Although anti-VEGF agents effectively inhibit pathological angiogenesis[51], they may simultaneously disrupt physiological vascular homeostasis[49]. This highlights the importance of developing targeted therapies that selectively modulate pathways differentiating physiological from pathological vasculature, such as mitochondrial dynamics regulation[46] or IL-33 isoform-specific signaling[52], thereby suppressing aberrant vessel growth while preserving normal retinal microcirculation.

1.4 Retinal vasculature: Technological advances and clinical implications

The retinal vasculature, with its distinctive anatomical and physiological characteristics, serves as an exemplary model for microcirculatory investigations. As the retina provides the only vascular network that can be directly observed noninvasively in humans, real-time retinal vascular monitoring provides significant clinical value, with its pathological changes correlating not only with various blinding ocular disorders but also serving as indicators of systemic conditions. Optical coherence tomography angiography (OCTA) represents a substantial advancement over conventional angiography techniques, permitting noninvasive, high-resolution evaluation of both vascular morphology and hemodynamic parameters[53-54]. This technology enables precise discrimination among four distinct retinal vascular plexuses while detecting diabetic microvascular changes 6-12 months earlier than traditional approaches, in addition to providing valuable insights for early detection and monitoring of systemic diseases such as hypertension and coronary artery disease (CAD)[55].

Nanotechnology has revolutionized therapeutic approaches through several innovations: Sustained-release anti-VEGF liposomes[56-57], exosomes as efficient vehicles for gene-editing systems[57], and bioprinting technology for constructing functional vascular networks[56]. In research models, induced pluripotent stem cell (iPSC)-derived retinal organoids accurately replicate human retinal development[58-59], whereas microfluidic retinal chips address static culture limitations by simulating dynamic BRB microenvironments[60-61], though further improvements in vascular network maturation remain necessary[62]. Artificial intelligence (AI)-enhanced analytical methods have markedly improved the precision of retinal vascular parameter quantification, establishing these metrics as potential biomarkers for cardiovascular risk assessment[63-64]. Contemporary research is evolving toward integrated multimodal and high-content analytical approaches, highlighting retinal vascular abnormalities as pivotal connections between localized pathology and systemic health status[65-66]. These advances contribute substantially to our comprehension of retinal vascular pathologies while simultaneously creating new research pathways for systemic microcirculatory investigations.

2 Polarization of microglia

2.1 Development of microglia

Microglia, the earliest immune cells to emerge in neural tissues, originate from primitive macrophage precursors in the yolk sac that migrate to and colonize the neural tube during early embryogenesis, a process tightly regulated by myeloid-specific transcription factors[67-68]. Microglia demonstrate extraordinary morphological plasticity, capable of undergoing rapid and dynamic transformations that correlate with their functional states and environmental cues. Under physiological homeostasis, microglial cells exhibit a characteristic highly ramified morphology in their “resting state” with continuously extending and retracting processes that enable comprehensive microenvironmental surveillance[69]. In contrast, under pathological conditions including inflammatory responses, tissue injury, or neurodegenerative processes, these cells undergo distinct morphological changes, adopting an amoeboid “activated” phenotype marked by significant cell body enlargement and substantial process retraction[70]. Functionally, microglia display remarkable pleiotropy: they dynamically monitor the neural microenvironment to regulate synaptic pruning and neural circuit refinement[67], while also playing essential roles in fundamental processes such as myelin homeostasis[71] and apoptotic cell clearance[72-73]. Their functional states are critically dependent on local microenvironmental signals.

Research on the retina often fails to adequately distinguish resident microglia from infiltrating peripherally derived macrophages, given their overlapping phenotypes and functions. A clear separation between these cell types must therefore be established from the outset. Upon activation, they exhibit several common features: Morphologically, both transition to an amoeboid form and express pan-myeloid markers like ionized calcium-binding adapter molecule 1 (Iba1) and CD11b; functionally, each can polarize toward M1 or M2 states and react to shared hypoxic and inflammatory cues, including HIF-1α and VEGF; pathologically, both contribute to the neovascular niche by releasing mediators such as matrix metalloproteinases (MMP) and cytokines[74]. Despite these parallels, resident microglia are fundamentally different in origin and behavior. Unlike peripheral macrophages[75], which derive from bone marrow hematopoietic stem cells and infiltrate only after blood-retinal barrier breakdown, microglia arise from yolk-sac-derived primitive myeloid progenitors[76]. They settle permanently in the retina during early embryonic development and sustain their numbers via local self-renewal. A defining trait of microglia is their constitutive expression of identity genes such as P2RY12 and Tmem119[77]. These molecular signatures not only provide a reliable means to distinguish microglia from peripherally derived macrophages, but also underpin their role as dedicated retinal immune sentinels. Equipped with this innate surveillance capability, microglia react swiftly to initial injury, orchestrating localized immune modulation[78]. In comparison, macrophage entry typically occurs later, as part of a secondary wave after barrier damage[77]. Therefore, accurately distinguishing between them by integrating lineage-tracing techniques and multi-marker profiling will enable us to more clearly elucidate the independent mechanisms and regulatory potential of microglia themselves in the initiation and progression of the disease.

2.2 Microglia in retinal homeostasis and disease

In the healthy retina, microglial cells predominantly localize to the inner plexiform layer (IPL) and outer plexiform layer (OPL), with emerging evidence supporting their sparse presence in the ganglion cell layer (GCL). These resident immune cells display a characteristic ramified morphology in their quiescent state, extending processes to the retinal vasculature to maintain vascular integrity and tissue homeostasis[79]. Pathological conditions induce significant spatiotemporal reorganization of microglia (Supplementary Figure 3,https://doi.org/10.57760/sciencedb.xbyxb.00106). In ischemic retinopathy models, they exhibit directed migration and form dense aggregates in hypoxic zones[80]. Notably, under pathological conditions, microglial density in superficial retinal layers increases progressively during postnatal development (P12 to P30), accompanied by morphological transformation from ramified to amoeboid phenotypes. This shift correlates with elevated expression of activation markers including CD68[81-82].

Dysregulated microglial activation contributes to various vision-threatening disorders. In diabetic retinopathy, M2-polarized microglia mitigate vascular damage through anti-inflammatory cytokine secretion and tissue repair[22], while in experimental autoimmune uveitis, enhanced Yin Yang 1 (YY1) lactylation potentiates microglial activation and disease progression[83]. Microglia also contribute significantly to other ocular diseases, such as retinitis pigmentosa (RP)[84], glaucoma[85], and age-related macular degeneration[86]. Recent single-cell omics approaches underscore the importance of precisely defining microglial functional states and their pathological contributions[87], considering their dual capacity for neuroprotection and pro-inflammatory responses[88-89]. This functional plasticity emphasizes the therapeutic potential of selectively modulating specific microglial subsets.

2.3 Classical classification of microglial polarization

Initial investigations classified microglia into dichotomous pro-inflammatory M1 or anti-inflammatory M2 polarized states as mutually exclusive categories[90-91]. Microglia display distinct morphological phenotypes corresponding to their activation states: The non-polarized state (M0) maintains a ramified resting morphology; M1 polarization induces an amoeboid transformation with shortened, thickened processes; while M2 polarization promotes extended, highly branched processes. These structural alterations directly reflect their functional immune adaptations[92].

In retinal pathologies, M1-polarized microglia primarily exert neurotoxic effects. DR models demonstrate that M1 microglia upregulate inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), inducing microvascular endothelial apoptosis and BRB compromise[22]. In both AMD and RP, M1 microglia localize to photoreceptor degeneration areas, where their secreted MMPs directly impair photoreceptors and stimulate complement activation[84, 86]. M2-polarized microglia mediate diverse neuroprotective functions in the retinal homeostasis. In DR, M2-derived exosomes facilitate microvascular repair through the microRNA-124 (miR-124)/Notch signaling axis[22]. These cells also attenuate ferroptosis by activating the glutathione peroxidase 4 (GPX4)/solute carrier family 7 member 11 (SLC7A11) pathway while enhancing phagocytic clearance of apoptotic photoreceptor remnants[84].

Deepening research on microglial polarization has uncovered an unexpectedly intricate involvement of these cells in retinal vascular regulation. Current findings demonstrate that M2 microglia can actively fuel pathological blood vessel formation in disease-specific contexts. A clear example can be observed in pituitary adenylate cyclase-activating polypeptide 38 (PACAP38) stimulation: This peptide promotes a shift of microglia toward an M2-like phenotype[93]. While this transition reduces inflammation and aids tissue repair, it also increases the expression of key pro-angiogenic factors such as Anexelekto (Axl), IL-3, and MMP14, which together promote abnormal blood vessel growth. Importantly, M2 microglia retain the ability to release potent angiogenic signals such as VEGF and PDGF even when displaying anti‑inflammatory characteristics, thereby directly stimulating the development of permeable and architecturally disorganized pathological vasculature[94]. Microglial M2 polarization exerts a bidirectional and dynamic regulatory effect on retinal vascular adaptive responses. Specifically, during physiological repair phases, it facilitates anti-inflammatory activity and promotes orderly vascular reconstruction, and in vascular maturation stages, it reinforces barrier integrity to establish vascular homeostasis. However, under persistent pathological stimulation, it can adopt a pro-angiogenic phenotype that exacerbates aberrant neovascularization. Recent work[50] has identified pathological retinal angiogenesis-associated glycolytic macrophages/microglia (PRAGMs) that co-express M1/M2 markers and play ambivalent roles in DR pathogenesis. These findings collectively indicate that the conventional M1/M2 dichotomy is inadequate for fully explaining the complex pathophysiological processes of retinal vasculature.

2.4 Non-classical classification of microglial polarization

Recent advancements in scientific technologies have transformed our comprehension of microglial heterogeneity in ophthalmology, demonstrating that the conventional binary classification system—categorizing microglia into pro-inflammatory (M1) and anti-inflammatory (M2) phenotypes—fails to fully capture the complexity of retinal microglial behavior[95-96]. Single-cell RNA sequencing (ScRNA-seq) studies[97-98] have revealed at least 6 distinct transcriptomic clusters in human retinal microglia, with specific subsets exhibiting marked upregulation of pro-inflammatory characteristics [14-fold increase in major histocompatibility complex (MHC) class I antigen presentation and 8.4-fold enhancement in positive regulation of T-cell immunity], while co-expressing canonical M2 markers. This apparent paradox underscores the retina’s unique microenvironment in shaping microglial molecular signatures[97, 99].

Transcriptomic analyses have identified a glycoprotein non-metastatic melanoma protein B (GPNMB)-positive subpopulation that expands aberrantly in PDR, displaying both profibrotic and fibrogenic features while maintaining gene expression profiles distinct from classical M1/M2 phenotypes or steady-state retinal microglia[100]. Self-formed ectodermal autonomous multi-zone (SEAM)-derived humanized retinal organoids have uncovered subpopulations with specific overexpression of the Krüppel-like factor 5 (KLF5) transcription factor, which dynamically modulates M1/M2 polarization by regulating the poly (ADP-ribose) polymerase family member 14 (PARP14)-signal transducer and activator of transcription 1/6 (STAT1/6) signaling axis—a metabolic reprogramming capacity that defies conventional classification paradigms[101-102].

Despite technological advances enabling refined microglial classification, critical challenges persist. Current studies[103-104] predominantly rely on static analyses, failing to capture the temporal dynamics of subpopulation transitions. For example, in ischemia-reperfusion (I/R) injury models, individual microglia can sequentially exhibit both pro-inflammatory and reparative features, with this phenotypic plasticity challenging conventional classification boundaries. Additionally, substantial discrepancies in clustering algorithms and marker genes across studies impede cross-study comparability. Notably, approximately 70% of identified subpopulations lack definitive functional annotations. Future research should integrate multi-omics (genomics, transcriptomics, proteomics, metabolomics) data with live imaging to delineate subpopulation-specific functions throughout disease progression, while employing humanized models for therapeutic target validation[105-106]. Overcoming these challenges will facilitate precision immunomodulation strategies and unveil novel therapeutic opportunities. More importantly, most recently identified non-classical microglial subsets remain largely characterized by single-cell transcriptomic profiling, with limited follow-up validation from foundational experimental studies. Consequently, their exact functional contributions, regulatory networks, and therapeutic relevance in retinal pathologies await further elucidation through more integrated and functionally oriented biological investigations.

3 Why do microglia polarize

3.1 Microglial polarization in neuroinflammation

As shown in Figure 1, during retinal neuroinflammation, inflammatory stimuli induce microglial polarization via intricate molecular mechanisms, critically contributing to the pathogenesis of diverse ocular diseases[107].

Upon exposure to pathogens, autoimmune insults, or metabolic disturbances, retinal microglia recognize danger signals through pattern recognition receptors, particularly Toll-like receptors (TLRs). This activation stimulates the nuclear factor kappa B (NF-κB)/NOD-like receptor family pyrin domain containing 3 (NLRP3) pathway, driving pro-inflammatory M1 polarization and promoting the secretion of pro-inflammatory cytokines[108]. In contrast, M2-polarized microglia facilitate microvascular repair via exosome-dependent mechanisms in diabetic retinopathy[22], while microRNA-223-mediated TSP-1/miR-27a-5p/Smad3 signaling axis orchestrates anti-inflammatory phenotypic switching in retinopathy of prematurity[19, 109].

Beyond the classical M1/M2 dichotomy, cluster of differentiation 74-positive (CD74+) microglia constitute distinct subpopulations in the distal optic nerve in glaucoma models[92], whereas galectin-3 (gal-3)-expressing subsets demonstrate neuroprotective characteristics in AMD[86]. Polarized microglia exhibit profoundly divergent biological impacts: M1-type exacerbates neuronal injury and BRB breakdown via pro-inflammatory cytokine secretion[7, 83], while M2-type establishes a protective microenvironment through apoptotic debris clearance and other mechanisms[84]. These findings have spurred targeted therapeutic strategies, including IL-4-liposome conjugates and mesenchymal stem cell (MSC) transplantation to enhance M2 polarization[110-111], presenting innovative treatment avenues for inflammatory ocular disorders.

3.2 Microglial polarization in ischemia/hypoxia injury

Under ischemic or hypoxic microenvironmental conditions, microglial polarization plays a pivotal regulatory role in vascular homeostasis and neuronal survival[21, 38]. M1 polarization predominates during the early stages of ischemia/hypoxia, where oxygen deprivation activates the AIM2 inflammasome in microglia, leading to IL-1β precursor processing via the ASC/CASP1 axis and subsequent upregulation of M1 markers[20, 112]. Clinically, elevated M1-associated factors in the vitreous of diabetic retinopathy patients demonstrate significant correlation with microaneurysm formation[22]. The neuroprotective M2 polarization emerges during later phases, with bone marrow mesenchymal stem cell-derived exosomes enhancing M2 markers through the microRNA-330-5p/euchromatic histone lysine methyltransferase 2 (EHMT2)/C-X-C motif chemokine ligand 14 (CXCL14) signaling axis[20]. Single-cell sequencing has identified a distinct microglial subset (MG3) in OIR that maintains vascular homeostasis via exosomal transfer of miR-27a-5p[50]. Furthermore, recent investigations[84, 113] have revealed that circular RNA 0061183 (circ_0061183)/miR-98-5p/IL-10 axis-mediated epigenetic regulation dynamically modulates the interconversion between M1 and M2 phenotypes.

3.3 Microglial polarization in metabolic reprogramming

Metabolic reprogramming fundamentally regulates retinal microglial polarization. Physiologically, microglia maintain homeostasis through oxidative phosphorylation (OXPHOS), whereas pathological stimuli induce glycolytic activation and M1 polarization[108, 114]. A recent study[50] has revealed that retinal endothelial cells and microglia form a positive feedback loop through the lactate/6-phosphofructo-2-kinase (PFKFB3)/acetyl-coenzyme A axis, which drives pathological angiogenesis and inflammation. Interestingly, these cells exhibit increased expression of both M1 and M2 markers, hence being termed PRAGMs. Cordycepin (COR) mitigates Alzheimer’s disease (AD) progression by targeting mitochondrial hexokinase II (HKII) and pyruvate dehydrogenase kinase 2 (PDK2) in microglia. This modulation drives metabolic reprogramming, shifts microglial polarization from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype, and subsequently ameliorates the neuronal microenvironment while attenuating neuronal damage in AD[115-116]. This mechanism suggests that similar metabolic regulatory pathways may exist in retinal diseases.

Therapeutically, nanocarriers suppress aerobic glycolysis and glutamine metabolism to promote M1-to-M2 conversion[117]. Zinc compounds induce M2 polarization via nuclear factor erythroid 2-related factor 2/thioredoxin reductase (Nrf2/TrxR) axis-mediated redox regulation[118]. These findings establish microglial metabolic reprogramming mechanisms as crucial foundations for developing precision retinal therapies.

3.4 Microglial polarization in mechanical signal stimulation

Microglia demonstrate remarkable mechanosensitivity, undergoing phenotypic shifts through diverse signaling pathways to modulate retinal microenvironment homeostasis[119]. Mechanical stimuli promote M1 polarization by upregulating pro-inflammatory mediators including iNOS and IL-1β via NF-κB and mitogen-activated protein kinase (MAPK) pathway activation[120]. In glaucoma, elevated intraocular pressure mechanically induces CD74+ M1 microglia that exacerbate neuroinflammation[88, 92]. Conversely, 40 Hz γ-vibration induces M2 polarization through IL-10/IL-10 receptor 1 (IL-10R1) signaling[121], while shear stress enhances IL-10 production via ubiquitin-specific peptidase 19 (USP19)/forkhead box O1 (FOXO1) regulation in ischemia-reperfusion injury[122]. Mechanical stimulation also generates transitional phenotypes; retinal degeneration models show disease-associated microglia (DAM) co-expressing CD74 (M1) and CXCL14 (M2) markers[84], with polarization patterns frequency-dependent[115].

3.5 Microglial polarization in neurodegenerative diseases

A bidirectional interplay exists between neurodegenerative disorders and retinal microglial polarization. In M1 polarization, neurodegenerative processes activate the Toll-like receptor 4 (TLR4)/NF-κB pathway via damage-associated molecular patterns (DAMPs), upregulating pro-inflammatory mediators including iNOS and IL-1β[123]. In RP models, M1 polarization exacerbates photoreceptor degeneration through NLRP3 inflammasome activation[84, 116]. Conversely, M2 polarization exerts anti-inflammatory and neuroprotective effects in ocular neurodegeneration. In DR, minocycline modulates the STAT1/STAT6 pathway to inhibit M1 while promoting M2 polarization, thereby reducing neuronal apoptosis[21, 124]. Following retinal ischemia-reperfusion injury, M2 microglia release IL-10 to attenuate neuroinflammation and activate the Nrf2/TrxR axis to preserve redox balance, a dual protective mechanism also observed in Parkinson’s disease (PD)-associated retinopathy[118]. Diverse pathological stimuli can drive retinal microglial polarization, with the resultant phenotype (M1 pro-inflammatory or M2 anti-inflammatory) being stimulus-dependent, though the exact molecular determinants require further elucidation.

4 Role of microglial polarization in RNV

4.1 Overall effect

As shown in Figure 2, microglial polarization exhibits dual regulatory effects on RNV through both direct pro-angiogenic mechanisms and indirect immunomodulatory functions. Under hypoxic conditions, microglia upregulate YY1 protein expression via lactylation modification, directly stimulating the secretion of pro-angiogenic factors such as fibroblast growth factor 2 (FGF2), thereby exacerbating pathological RNV[21]. The polarization state critically influences immunomodulatory capacity: M1-polarized microglia aggravate pathological angiogenesis by activating inflammatory responses through the ASC/CASP1/IL-1β pathway[20], whereas M2 polarization attenuates inflammatory microenvironments through either IL-10 secretion[122] or miR-223-enriched exosomes release[109], consequently restoring vascular homeostasis. Intriguingly, in both DR and ROP, hyperglycemia induces microglial acquisition of a distinct PRAGM via histone acetylation reprogramming[50], underscoring the pivotal role of microglial polarization in the metabolic-immune-vascular triad during retinal vascular pathogenesis.

4.2 Direct effects

4.2.1 Direct cell-cell interactions

In the healthy retina, microglia form extensive contacts with blood vessels via their processes. High-resolution confocal microscopy confirms that microglial somata and projections directly attach to retinal capillaries, an interaction sustained throughout both developmental and adult stages[7]. Their terminal extensions exhibit broad associations with the vascular basement membrane, structurally resembling astrocytic end-feet. At the molecular level, microglia engage with basement membrane proteins—such as laminin, fibronectin, and collagen—through integrins (e.g., β1, α5β1, and αvβ3), contributing to cell migration, blood-retinal barrier maintenance, inflammatory regulation, and responses to pathological injury[125-126].

Under physiological conditions, microglia are not static but display continuous dynamic movement along vascular surfaces, monitoring vascular tension and integrity. In acute pathological contexts such as vascular occlusion models, they rapidly reorient and migrate to injury sites, forming physical barriers that envelop affected vessels[127]. Under chronic injury conditions, inflammatory stimuli (e.g., lipopolysaccharide or IL-1β) trigger vascular endothelial cells to overexpress adhesion molecules like VCAM-1, facilitating aberrant firm adhesion of microglia to the vessel wall. This results in perivascular cuffing and sustained M1 polarization[128].

In ocular diseases including ROP and DR, these intimate microglia-vessel connections exacerbate vascular damage by facilitating the release of harmful mediators from microglia. Moreover, pronounced perivascular accumulation of microglia disrupts the BRB, further amplifying tissue injury and establishing a vicious cycle[23].

4.2.2 Phagocytosis by microglia

As resident immune macrophages in the retina, microglia exhibit phagocytosis as a core function and demonstrate a dual role in their interactions with the vasculature, often characterized as a “double-edged sword”. Under homeostatic conditions, they serve as scavengers that clear senescent organelles and oxidative metabolites in the perivascular microenvironment, thereby preserving the structural and functional integrity of the BRB. During retinal vascular development, microglia accumulate behind vascular tip cells and employ phagocytosis to eliminate superfluous cellular connections and debris, thereby supporting precise vascular remodeling and facilitating the establishment of an optimized vascular architecture[38].

Under pathological conditions, however, the phagocytic capacity of microglia can become overwhelmed or impaired, resulting in inadequate clearance of cellular debris. This allows persistent accumulation of necrotic material and continuous release of pro-angiogenic factors[129]. In severe instances, activated microglia go beyond their typical scavenger function—no longer confined to clearing metabolic waste and apoptotic cells—and instead aberrantly target and phagocytize viable pericytes and endothelial cells, which exacerbates damage to both the structure and function of the BRB[129-130].

For instance, in diabetic retinopathy, microglial phagocytic activity initially exerts protective effects through the removal of toxic substrates in early disease phases. In advanced stages, however, phagocytic dysfunction and exhaustion diminish clearance efficiency and may lead to a pathogenic shift wherein microglia attack and engulf pericytes, directly promoting vascular disruption and leakage[131].

4.2.3 Mechanical traction

Conventional understanding posits that blood flow is primarily regulated by vascular smooth muscle cells and pericytes, under the control of neural and humoral signaling. Emerging evidence, however, indicates that microglia can mechanically modulate vascular diameter through direct physical contact[36]. Upon firm adhesion to ligands within the vascular basement membrane via integrins and other adhesion molecules, microglia generate inward or outward traction forces on the vessel wall through contraction of their actin cytoskeleton, thereby physically altering the capillary lumen. Additionally, microglia may facilitate vascular diameter changes by promoting angiotensin release[132].

In contrast to systemic hormonal or slower neural regulatory mechanisms, microglia enable rapid responses to the metabolic demands of individual capillary segments or even single synapses, allowing precise redistribution of blood flow to highly active retinal regions. Under physiological conditions, this mechanism is essential for supporting normal retinal function and visual signal processing[133].

In pathological contexts such as diabetic retinopathy or retinal ischemia, however, this finely tuned regulatory system becomes impaired. Microglia may exert sustained and excessive mechanical traction on vessels rather than provide transient and localized modulation. Such aberrant mechanical stress, together with microglia-derived inflammatory factors and reactive oxygen species, contributes to pericyte and endothelial cell injury, leading to persistent vasospasm, vascular occlusion, or pathological dilation. These alterations disrupt autoregulation of blood flow, exacerbate ischemia and hypoxia, and ultimately promote the development of pathological neovascularization[7].

4.2.4 Secretory factor regulation

In the retina, microglia dynamically modulate vascular status through the secretion of diverse mediators in a manner critically dependent on their functional polarization state.

Under reparative conditions, microglia adopt an M2 phenotype characterized by the release of protective factors that contribute to vascular homeostasis[22]. For instance, anti-inflammatory cytokines, including IL-10 and TGF-β, attenuate inflammatory responses and reinforce vascular barrier function[134-135], whereas PDGF facilitates pericyte recruitment and coverage, thereby promoting vascular maturation and stabilization[136]. In contrast, under pathological settings such as diabetic retinopathy, microglia predominantly polarize toward a pro-inflammatory M1 state and secrete deleterious mediators[137]. Key pro-inflammatory cytokines such as TNF-α and IL-1β downregulate endothelial junction protein expression, resulting in BRB disruption and increased vascular permeability[138].

In AMD, activated microglia critically regulate choroidal neovascularization progression and regression by dynamically modulating the secretory balance of growth factors and cytokines[86]. Consequently, microglia exert a context-dependent dual role in vascular regulation via their secretory activities, and the mechanisms governing their phenotypic switching have increasingly been recognized as promising therapeutic targets for retinal vascular disorders.

4.3 Indirect effects

4.3.1 Recruiting and activating other immune cells

In the retina, microglia function as central regulators of immune responses and play a pivotal role in both maintaining retinal vascular homeostasis and driving pathological processes through the recruitment and activation of other immune cells. Under normal physiological conditions or following mild injury, microglia secrete controlled levels of chemokines (e.g., CX3CL1) and anti-inflammatory factors (e.g., IL-10 and TGF-β), which recruit reparative monocytes and regulatory T cells (Tregs) to promote inflammation resolution, clear apoptotic debris, and support vascular normalization and remodeling—thereby preserving the structural and functional integrity of the BRB[15].

Under pathological conditions, however, microglia undergo M1 polarization and excessively secrete chemokines, resulting in substantial recruitment of neutrophils and pro-inflammatory monocytes. These infiltrating cells accumulate in perivascular regions and differentiate into macrophages, leading to disruption of vascular tight junctions, pericyte loss, and ultimately, breakdown of the BRB accompanied by pathological neovascularization[15, 139].

For instance, in diabetic retinopathy, persistent hyperglycemia activates microglia, driving overexpression of CCL2 and subsequent recruitment of large numbers of monocytes into retinal tissue. In concert with M1-polarized microglia, these cells establish a pro-inflammatory microenvironment. Through release of VEGF and other inflammatory mediators, they promote vascular leakage, tissue ischemia, and dysregulated activation of angiogenic signaling pathways—culminating in RNV and accelerated progression to the proliferative stage[16]. Hence, via immune cell recruitment mechanisms, microglia mediate protective functions under physiological conditions but evolve into key promoters of vascular pathology in disease states. These insights provide a critical theoretical foundation for developing targeted immunomodulatory therapies aimed at the retinal vascular microenvironment.

4.3.2 Regulating other components of the NVU-pericytes

The NVU serves as a fundamental functional entity responsible for maintaining microenvironmental homeostasis within the CNS, including the retina. Its essential constituents comprise neurons, diverse glial cells (e.g., astrocytes and microglia), vascular endothelial cells, and pericytes[140]. Within this intricately regulated network, microglia function as resident immune sentinels and participate in intensive bidirectional crosstalk with pericytes. Pericytes, ensheathing the abluminal surface of microvessels, play multifaceted roles encompassing the regulation of capillary tone, endothelial proliferation, vascular stability, and BRB integrity. Concurrently, microglia perpetually survey the microenvironment through highly dynamic processes. Both physical interconnections and molecular signaling between microglia and pericytes are pivotal in modulating retinal vasculature under both physiological and pathological contexts.

In models of DR, exosomes originating from M2-polarized microglia have been shown to attenuate pericyte apoptosis and enhance endothelial cell proliferation, thereby facilitating vascular repair and reducing leakage[22]. Moreover, microglia contribute to the preservation of the inner BRB (iBRB) via immunomodulatory pathways, including miR-155-mediated suppression of inflammatory responses, thereby ameliorating vascular amyloid deposition and pericyte degeneration[129].

In conclusion, microglia act as an immunological regulatory switch in retinal vascular homeostasis. Under physiological conditions, their tight coordination with pericytes helps sustain vascular integrity, whereas under pathological stimuli, aberrant microglial activation accelerates pericyte damage and vascular pathogenesis. Consequently, therapeutic targeting of the microglia-pericyte axis represents a promising innovative approach for the management of retinal vascular disorders.

4.3.3 Regulating other components of the NVU-glial cells

As pivotal immune regulators within the NVU, microglia engage in dynamic crosstalk with other glial cells, including astrocytes and Müller cells, to collectively sustain the structural and functional integrity of retinal vasculature.

Microglia orchestrate sophisticated regulatory networks during retinal vascular development. Their depletion reduces inner retinal vascular density while downregulating glutamine synthetase (GS) expression in Müller cells―this rate-limiting enzyme for glutamine biosynthesis critically regulates angiogenesis[141]. Mechanistically, microglia control inner vascular plexus formation by modulating VEGFA isoform expression in Müller cells[141]. Intriguingly, they also facilitate deep plexus development through Müller cell-dependent Wnt/β-catenin signaling[141]. During superficial plexus formation, microglia guide angiogenesis by modulating astrocyte-mediated semaphorin 3A (SEMA3A) secretion[7]. Furthermore, in glaucoma models, microglia-astrocyte crosstalk via adenosine triphosphate (ATP)/P2X purinoceptor 7 (P2X7R) signaling fine-tunes neurovascular coupling[142].

Thus, microglia modulate the functional states of NVU components such as astrocytes and Müller cells, and targeting these interactive pathways may provide novel therapeutic strategies for retinal vascular disorders.

5 Other types of microglia

5.1 Proangiogenic microglia

Proangiogenic microglia (PRAM) constitute a functionally distinct immune cell subset within the retina, characterized by their high expression of activation markers, glycolytic enzymes, and proangiogenic factors such as insulin-like growth factor 1 (IGF-1). These cells are predominantly localized within or adjacent to nascent vascular clusters[143]. Under physiological conditions, PRAM contribute to developmental retinal vascularization through neurovascular coupling, whereby they monitor neuronal activity and guide vascular sprouting into avascular zones[137]. Their proangiogenic activity is primarily mediated by the secretion of vasoactive factors such as VEGF and the activation of the phosphoinositide 3-kinase (PI3K)-AKT signaling pathway, which collectively promote endothelial cell migration and tubulogenesis[144]. In pathological contexts, including diabetic retinopathy and OIR, aberrant PRAM activation exacerbates pathological neovascularization. This is accompanied by the disruption of the BRB through the release of inflammatory factors, ultimately resulting in secondary neuronal death[137, 139]. A study[145] demonstrates that neuropilin-1 (NRP-1)-positive PRAM directly facilitate abnormal retinal vascular anastomosis via chemotaxis, with specific NRP-1 knockout shown to reduce pathological vascular growth by 65%. Consequently, targeting specific activated PRAM subpopulations emerges as a promising therapeutic strategy for conditions such as ROP and other ocular disorders involving microglia-driven RNV (e.g., PDR) or choroidal neovascularization (e.g., age-related macular degeneration)[137, 146].

5.2 sMG2 microglia

Within the retinal vascular system, sMG2 microglia constitute a recently characterized cellular subset intimately linked to necroptosis, defined by their high expression of pivotal necroptosis-related genes, RIP3 and MLKL[147]. Hypoxic conditions activate this subpopulation, prompting the release of pro-inflammatory factors through the receptor-interacting protein kinase (RIP) 1/RIP3-dependent necroptosis pathway. This cascade establishes a distinctive “necroptosis-FGF2 axis”, which directly modulates angiogenesis[147-148]. Under physiological circumstances, sMG2 microglia may contribute to vascular tone regulation via interactions with blood vessels and neural synapses. Their CD39/CD73-positive processes establish “purinergic connections” with the vasculature, thereby supporting BRB integrity[131, 149]. Under pathological states, however, such as diabetic retinopathy or OIR, aberrant sMG2 activation exacerbates neuroinflammation and facilitates vascular leakage and pathological neovascularization, partly mediated by the release of factors such as VEGF[147, 150]. Notably, inhibiting sMG2-mediated necroptosis—for instance, using GSK-872 to block RIP3—markedly improves retinal vascular pathology[150]. Concurrently, combined therapeutic targeting of VEGF and the necroptosis pathway (e.g., employing a PDGF receptor β antibody alongside a necroptosis inhibitor) yields a synergistic anti-angiogenic response[131]. Collectively, these observations indicate that modulating sMG2 activation represents a promising novel therapeutic avenue for retinal vascular diseases, particularly through interventions targeting the TLR4-RIP3-mixed lineage kinase domain-like (MLKL) signaling axis to mitigate its pro-inflammatory and pro-angiogenic functions[148, 150].

5.3 MG3 microglia

MG3 microglia constitute a functionally distinct immune cell subset in the retina, predominantly characterized by high expression of TSP-1, an extracellular matrix protein exhibiting potent anti-angiogenic properties[19]. Under physiological conditions, MG3 helps maintain retinal vascular homeostasis through constitutive TSP-1 expression, which suppresses aberrant vascular proliferation. Single-cell transcriptomic analyses indicate that MG3 share molecular signatures with anti-angiogenic microglial populations originating from the spinal cord. In the OIR model, TSP-1 secreted by MG3 has been shown to significantly suppress pathological neovascularization. Under pathological conditions such as diabetic retinopathy, a decrease in MG3 abundance may compromise TSP-1-mediated vascular inhibition, thereby accelerating RNV[19, 22]. Notably, in both diabetic and OIR models, activated microglia participate in retinal microvascular pathogenesis, whereas targeted enhancement of TSP-1 expression alleviates vascular leakage and improves pericyte coverage[137, 151]. Therapeutically, specific knockout of the pro-inflammatory factor miR-155 using gene-editing techniques facilitates the transition of MG3-like cells toward a protective phenotype, mitigating retinal vascular pathology[152]. Additionally, emerging strategies such as exosome-mediated TSP-1 delivery or pharmacological modulation of the CD39/CD73 purinergic signaling pathway represent promising avenues for regulating MG3 function[137, 149]. These findings collectively provide an important theoretical basis for targeting MG3 in the treatment of retinal vascular diseases.

5.4 PRAGMs

PRAGMs constitute a distinct microglial subpopulation identified in retinal ischemic diseases. These cells display a unique pro-angiogenic phenotype, marked by the concurrent high expression of M1 and M2 polarization markers and enhanced secretion of both pro-inflammatory and pro-angiogenic cytokines[50]. Molecular profiling[143] reveals that PRAGMs significantly upregulate activation markers, key glycolytic enzymes, and pro-angiogenic factors, and are spatially localized predominantly around nascent vascular clusters. Under physiological conditions, retinal microglia contribute to vascular development and homeostasis by secreting factors including VEGF[23, 141]; indeed, microglial depletion has been shown to reduce inner retinal vascular density and downregulate VEGFA subtype transcription[141]. Under pathological conditions, however, PRAGMs drive pathological RNV via neurovascular coupling mechanisms under hypoxic stress, guiding vascular growth into avascular regions like the outer nuclear layer and macular area[137]. Their sustained activation exacerbates BRB disruption, leading to secondary neuronal death[137]. Notably, the PRAGM phenotype can be reproduced in bone marrow-derived macrophages or retinal microglia upon stimulation with HIF-1α and IL-1β[50]. Moreover, modulation of key signaling molecules such as interferon regulatory factor 1 (IRF1) has proven effective in mitigating microglia activation-associated retinal inflammation[153], thereby revealing novel potential targets for the treatment of retinal neovascular diseases.

6 Clinical translation

Retinal neovascular diseases constitute a major cause of vision impairment, with pathogenesis involving hypoxia-driven aberrant angiogenesis and associated inflammatory responses. Current evidence[19] establishes retinal microglia as dual regulators of pathological neovascularization. Hypoxia-induced microglial polarization produces both pro-angiogenic and anti-angiogenic mediators, with an imbalance directly affecting disease progression[19, 21].

ScRNA-seq in OIR models[19] has uncovered substantial microglial heterogeneity, particularly the MG3 subpopulation demonstrating unique anti-angiogenic characteristics. These cells utilize TSP-1 to transport miR-27a-5p via exosomes, potently inhibiting endothelial migration[19]. The colony stimulating factor 1 receptor (CSF1R) inhibitor PLX3397 effectively suppresses pathological angiogenesis and has advanced to phase II clinical trials for AMD, yet concerns remain about its long-term immunosuppressive effects[84, 152].

Nanocarrier technology has markedly enhanced targeting precision. For example, mitochondria-directed platinum nanozymes achieve single-dose neovascularization suppression in ROP models via ROS scavenging and hypoxia mitigation[154-155]. Although these nanotherapeutics have completed preclinical safety assessments, challenges persist regarding manufacturing scalability and chronic toxicity[154]. Moreover, the clinical application of nanocarriers faces multiple limitations, including risks associated with biocompatibility and long-term retention toxicity, as well as the impact of pathological microenvironment heterogeneity on delivery efficiency.

Advances in single-cell multi-omics and spatial transcriptomics are enabling precise targeting of specific microglial subpopulations, laying an important foundation for developing targeted therapies. However, most current conclusions are still largely derived from single-cell transcriptomic data and have not yet been fully validated through genetic manipulation or direct functional intervention experiments. Due to the lack of causal evidence, many potential therapeutic targets remain theoretical and require further confirmation in more systematic experimental models.

In summary, the integration of multidimensional strategies positions the field to systematically address the translational challenges in microglia-targeted therapy, paving the way for novel and precise therapeutic alternatives for retinal vascular diseases that move beyond current anti‑VEGF paradigms.

7 Discussion

Emerging evidence[156] unequivocally supports the central role of microglial polarization in regulating the pathogenesis of RNV. This review consolidates findings demonstrating that RNV progression is not solely driven by the classical hypoxia-VEGF axis but is also critically coordinated by the dynamic dual functions of retinal microglia across distinct polarization states—ranging from the conventional M1/M2 dichotomy to more complex non-classical phenotypes[157]. Pro-inflammatory M1-polarized microglia directly aggravate pathological angiogenesis and disrupt the BRB via the release of soluble factors such as VEGF, TNF-α, and IL-1β, along with activation of key signaling pathways including HIF-1α/NF-κB[158]. In contrast, anti-inflammatory M2-polarized microglia primarily foster vascular homeostasis and repair mechanisms through the secretion of IGF-1 and TSP-1, although their functional influence may shift toward adverse effects depending on the microenvironment[19]. Notably, recently identified specialized non-classical subsets (such as PRAGMs, sMG2, and MG3) reveal remarkable functional heterogeneity and context-dependent plasticity among retinal microglia, challenging the traditional M1/M2 binary classification and calling for a more refined understanding of their contributions to RNV[50]. Here, we present the first systematic integration of single-cell omics and other cutting-edge technologies to decipher the relationship between microglial heterogeneity and RNV. Concurrently, we explore groundbreaking strategies for modulating microglial function, offering transformative therapeutic potential for ischemic retinopathies.

A range of pathological stimuli—such as neuroinflammation, ischemia/hypoxia, metabolic reprogramming, mechanical signals, and neurodegenerative pathologies—can trigger the functional polarization of microglia, consequently influencing the progression of RNV. Polarized microglia play a pivotal regulatory role in RNV through both direct and indirect mechanisms. Directly, they modulate vascular structure and function, either promoting or inhibiting neovascularization, via physical contact with vascular endothelial cells, phagocytic activity, mechanical traction, and the release of vasoactive factors. Indirectly, microglia not only activate and recruit peripheral immune cells through chemokine secretion, thereby amplifying inflammatory and vascular responses[19], but also, as core constituents of the NVU, participate in intricate interactive networks with pericytes, astrocytes, and other cells via intercellular signaling. These interactions collectively shape the angiogenic microenvironment and indirectly modulate the direction and magnitude of RNV[7]. In summary, microglia exert a central regulatory influence on RNV through diverse direct actions and NVU-wide indirect coordination[159].

Traditionally, microglia have been categorized based on 2 main activation states: The pro-inflammatory M1 type and the anti-inflammatory M2 type. Given the established link between inflammatory processes and retinal vascular growth, earlier research largely supported the view that M1 activation predominantly fuels abnormal blood vessel formation, while M2 activation supports vascular integrity and tissue healing. However, more recent work reveals that in pathological settings, such as hypoxia and oxidative stress, M2-polarized microglia are also capable of releasing factors that stimulate angiogenesis, such as VEGF and PDGF[93-94]. This indicates their potential involvement in worsening pathological neovascularization in the retina. Such evidence implies that the M1 and M2 states are not rigidly distinct categories but rather exist along a fluid and overlapping functional continuum. Thus, therapeutic approaches aimed at microglia should avoid oversimplified attempts to merely “convert M1 into M2”. At the same time, modern techniques, such as single-cell transcriptomics are shedding new light on the diverse roles microglia can play[143]. In disease conditions, these cells may adopt various non‑traditional functional profiles. Examples include PRAGMs, MG3, and sMG2, each contributing to angiogenesis in ways that are nuanced and heavily influenced by the surrounding pathological environment.

Microglia display remarkable functional heterogeneity, presenting substantial therapeutic challenges since current strategies cannot effectively differentiate between their pro-inflammatory and neuroprotective subpopulations. Although specialized retinal microglial subsets with neuroprotective functions have been identified, non-selective interventions may inadvertently impair their essential roles in preserving BRB integrity and immune privilege[160-161]. Drug delivery poses further obstacles, as the BRB prevents over 95% of systemically administered therapeutics from reaching the retina, while localized injections often fail to maintain stable drug concentrations[162]. Additionally, the retina’s unique immune-privileged status further complicates the development of targeted therapies.

Current clinical evaluation systems are also limited by their overreliance on anatomical parameters such as vascular leakage while disregarding the neuroprotective effects of microglial modulation. A study[163] indicates that targets like μ-opioid receptors can mediate transcellular neuroprotection, yet such mechanisms are often omitted from conventional assessment paradigms. Moreover, microenvironmental factors, including astrocyte-mediated microglial regulation via cyclic adenosine monophosphate (cAMP) signaling, which promotes neuroprotection[164], remain inadequately integrated into therapeutic evaluation frameworks.

Microglia are pivotal regulators of retinal vascular equilibrium and also actively contribute to aberrant blood vessel growth in disease. As a result, focusing on their activation states and functional roles is increasingly viewed as a valuable and forward-looking approach for treating retinal vascular disorders. Nevertheless, moving such microglia-directed treatments from bench to bedside presents a number of substantial obstacles. To begin with, the behavior of microglia is remarkably fluid and shaped by their surroundings[165]. Their functional profiles and activity levels shift continually as pathology advances and local signals change. This reality means that therapies cannot be designed around fixed categories such as “pro-inflammatory” or “anti-inflammatory” but must instead account for precise timing and location to distinguish beneficial from harmful responses. Additionally, microglia serve dual—and equally vital—physiological roles in the retina. Apart from participating in damaging vessel growth, they are critical for preserving immune balance, upholding the BRB, and facilitating synaptic refinement. Broad or prolonged suppression of microglial activity to curb neovascularization risks compromising their ability to protect neurons and monitor immune threats, which could in turn aggravate neuroinflammation or leave the retina more vulnerable to infection. Finally, a persistent gap separates animal models from the reality of human disease. While widely used animal systems capture certain aspects of human pathology, they fall short of fully mirroring the disease course observed in patients. One clear example is the absence of a macula in the mouse retina—a structure essential for sharp central vision in people and a common locus of degenerative change[84]. Consequently, interventions that prove effective in animals cannot be assumed to work similarly in the clinical setting.

Given these considerations, directing therapies toward microglia in retinal vascular conditions continues to confront substantial hurdles, and advancing such treatments into clinical use will require sustained effort. A primary step forward involves combining in vivo real-time imaging with advanced profiling methods like single-cell and spatial multi-omics. Together, these tools allow researchers to map how microglial characteristics change over time and space during disease and to study their crosstalk with blood vessels. From this detailed view, critical molecular switches that steer microglia toward harmful states can be pinpointed, paving the way for finely tuned therapeutic adjustments. Another essential aim is to design modulation strategies that distinguish between disease-promoting and health-supporting microglial activities. One attractive possibility lies in staged, time-sensitive treatment protocols—curtailing vessel-stimulating actions in early or active disease stages, then encouraging microglial functions that aid tissue repair and stability later on. Adjusting specific disease-driving pathways, like those involving HIF-1α or NF-κB, with high precision offers a complementary route. Furthermore, newer experimental platforms are helping to bridge the gap between laboratory findings and human patients. Retinal organoids grown from patient-derived stem cells, especially when paired with microfluidic chip systems that mimic tissue environments, can reproduce disease-specific changes outside the body[162-163]. These setups become vital for testing how well and how safely potential microglia-focused treatments work in a human context.

In closing, even though the journey from discovery to clinic is lined with difficulties, merging state-of-the-art tools, creative treatment designs, and biologically faithful models points toward a promising direction. Successfully engaging microglia—a central player where neural, immune, and vascular systems meet—could eventually lead to more tailored and effective management of retinal vascular disorders.

8 Conclusion

Microglial polarization is a pivotal event in the pathogenesis of RNV. This review has delineated the dual role of polarized microglia: The pro-inflammatory M1 phenotype exacerbates vascular injury and pathological angiogenesis, whereas the anti-inflammatory M2 phenotype facilitates vascular repair, inflammatory resolution, and tissue homeostasis. Notably, advances in single-cell sequencing and related technologies have revealed that microglia in disease contexts exhibit complex polarization spectra beyond the conventional M1/M2 dichotomy, underscoring their considerable heterogeneity and plasticity. The dynamic equilibrium among these polarization states, shaped by the local microenvironment, ultimately dictates the fate of retinal neurons and vasculature. A deeper understanding of the molecular switches governing microglial polarization—such as specific signaling pathways and epigenetic regulators—opens promising therapeutic avenues. Future therapeutic strategies designed to precisely modulate microglial polarization, for example by selectively inhibiting detrimental responses or promoting beneficial functions, hold significant potential to halt disease progression and preserve vision in patients with neovascular retinal diseases. Thus, targeting microglial polarization represents a novel and powerful paradigm for treating these blinding conditions.

参考文献

[1]

Selvam S, Kumar T, Fruttiger M. Retinal vasculature development in health and disease[J]. Prog Retin Eye Res, 2018, 63: 1-19.

[2]

Wert KJ, Mahajan VB, Zhang L, et al. Neuroretinal hypoxic signaling in a new preclinical murine model for proliferative diabetic retinopathy[J]. Signal Transduct Target Ther, 2016, 1: 16005.

[3]

Askie LM, Darlow BA, Finer N, et al. Association between oxygen saturation targeting and death or disability in extremely preterm infants in the neonatal oxygenation prospective Meta-analysis collaboration[J]. JAMA, 2018, 319(21): 2190-2201.

[4]

Yuan X, Ruan W, Bobrow B, et al. Targeting hypoxia-inducible factors: therapeutic opportunities and challenges[J]. Nat Rev Drug Discov, 2024, 23(3): 175-200.

[5]

Fu T, Sullivan DP, Gonzalez AM, et al. Mechanotransduction via endothelial adhesion molecule CD31 initiates transmigration and reveals a role for VEGFR2 in diapedesis[J]. Immunity, 2023, 56(10): 2311-2324.

[6]

Zhang QY, Zhang HY, Feng SG, et al. Macrophage metabolic reprogramming ameliorates diabetes-induced microvascular dysfunction[J]. Redox Biol, 2025, 79: 103449.

[7]

Jobling AI, Greferath U, Dixon MA, et al. Microglial regulation of the retinal vasculature in health and during the pathology associated with diabetes[J]. Prog Retin Eye Res, 2025, 106: 101349.

[8]

Yang Z, Wang T, Wu D, et al. RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer[J]. J Exp Clin Cancer Res, 2020, 39(1): 203.

[9]

Pérez-Gutiérrez L, Ferrara N. Biology and therapeutic targeting of vascular endothelial growth factor A[J]. Nat Rev Mol Cell Biol, 2023, 24(11): 816-834.

[10]

Reddy SK, Devi V, Seetharaman ATM, et al. Cell and molecular targeted therapies for diabetic retinopathy[J]. Front Endocrinol (Lausanne), 2024, 15: 1416668.

[11]

Antoszyk AN, Glassman AR, Beaulieu WT, et al. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: A randomized clinical trial[J]. JAMA, 2020, 324(23): 2383-2395.

[12]

Bressler NM, Beck RW, Ferris FL. Panretinal photocoagulation for proliferative diabetic retinopathy[J]. N Engl J Med, 2011, 365(16): 1520-1526.

[13]

Ghena N, Anderson SR, Roberts JM, et al. CD11c-expressing microglia are transient, driven by interactions with apoptotic cells[J]. Glia, 2024, 73(5): 1077-1089.

[14]

王快, 杨宇. 阿尔茨海默病中小胶质细胞相关易感基因及其作用机制的研究进展[J]. 吉林大学学报(医学版), 2025, 51(1): 255-265.

[15]

WANG Kuai, YANG Yu. Research progress in microglia-related susceptibility genes in Alzheimer’s disease and their mechanisms [J]. Journal of Jilin University.Medicine Edition, 2025, 51(1): 255-265.

[16]

Xiao R, Huang X, Gao S, et al. Microglia in retinal diseases: From pathogenesis towards therapeutic strategies[J]. Biochem Pharmacol, 2024, 230(Pt 1): 116550.

[17]

Chen L, Zhang H, Zhang Y, et al. Ganglion cell-derived LysoPS induces retinal neovascularisation by activating the microglial GPR34-PI3K-AKT-NINJ1 axis[J]. J Neuroinflammation, 2024, 21(1): 278.

[18]

Yang Y, Ke J, Cao Y, et al. Melatonin regulates microglial M1/M2 polarization via AMPKα2-mediated mitophagy in attenuating sepsis-associated encephalopathy[J]. Biomed Pharmacother, 2024, 177: 117092.

[19]

Yamaguchi M, Nakao S, Arima M, et al. Heterotypic macrophages/microglia differentially contribute to retinal ischaemia and neovascularisation[J]. Diabetologia, 2024, 67(10): 2329-2345.

[20]

Luo Q, Jiang Z, Jiang J, et al. Tsp-1(+) microglia attenuate retinal neovascularization by maintaining the expression of Smad3 in endothelial cells through exosomes with decreased miR-27a-5p[J]. Theranostics, 2023, 13(11): 3689-3706.

[21]

Liu X, Zhou Q, Meng J, et al. Autophagy-mediated activation of the AIM2 inflammasome enhances M1 polarization of microglia and exacerbates retinal neovascularization[J/OL]. MedComm (2020), 2024, 5(8): e668[2025-11-01].

[22]

Wang X, Fan W, Li N, et al. YY1 lactylation in microglia promotes angiogenesis through transcription activation-mediated upregulation of FGF2[J]. Genome Biol, 2023, 24(1): 87.

[23]

Wang X, Xu C, Bian C, et al. M2 microglia-derived exosomes promote vascular remodeling in diabetic retinopathy[J]. J Nanobiotechnology, 2024, 22(1): 56.

[24]

Alves CH, Fernandes R, Santiago AR, et al. Microglia contribution to the regulation of the retinal and choroidal vasculature in age-related macular degeneration[J]. Cells, 2020, 9(5): 1217.

[25]

Scharf J, Freund KB, Sadda S, et al. Paracentral acute middle maculopathy and the organization of the retinal capillary plexuses[J]. Prog Retin Eye Res, 2021, 81: 100884.

[26]

Niu Y, Xi Y, Jing Y, et al. Endothelial Notch signaling regulates the function of the retinal pigment epithelial barrier via EC angiocrine signaling[J]. Antioxidants (Basel), 2023, 12(11): 1979.

[27]

Dragoni S, Moccia F, Bootman MD. The roles of transient receptor potential (TRP) channels underlying aberrant calcium signaling in blood-retinal barrier dysfunction[J/OL]. Cold Spring Harb Perspect Biol, 2025, 17(2): a041763[2025-11-01].

[28]

Zarekiani P, Nogueira Pinto H, Hol EM, et al. The neurovascular unit in leukodystrophies: towards solving the puzzle[J]. Fluids Barriers CNS, 2022, 19(1): 18.

[29]

Seo S, Choi CH, Yi KS, et al. An engineered neurovascular unit for modeling neuroinflammation[J/OL]. Biofabrication, 2021, 13(3)[2025-11-01].

[30]

Sha L, Zhao Y, Li S, et al. Insights to Ang/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases[J]. J Transl Med, 2024, 22(1): 898.

[31]

Alarcon-Martinez L, Villafranca-Baughman D, Quintero H, et al. Interpericyte tunnelling nanotubes regulate neurovascular coupling[J]. Nature, 2020, 585(7823): 91-95.

[32]

Yang Y, Chen H, Liu Q, et al. Elucidating molecular pathogenesis and developing targeted therapeutic interventions for cerebrovascular endothelial cell-mediated vascular dementia[J]. Front Aging Neurosci, 2025, 17: 1623050.

[33]

Zhao D, Yi Y, He Q, et al. Exploring the regulatory mechanism of Nao Tai Fang on vascular Dementia’s biological network based on cheminformatics and transcriptomics strategy[J]. J Ethnopharmacol, 2021, 274: 114065.

[34]

Lambrichts SMP, van Oostenbrugge RJ, Foulquier S. TRPV4 in cerebral small vessel disease: a key interacting partner[J]. Vasc Pharmacol, 2025, 159: 107492.

[35]

Plotnikov MB, Anishchenko AM, Khlebnikov AI, et al. Regulation of blood-brain barrier permeability via JNK signaling pathway: mechanisms and potential therapeutic strategies for ischemic stroke, Alzheimer’s disease and brain tumors[J]. Molecules, 2025, 30(11): 2353.

[36]

Silla A, Punzo A, Caliceti C, et al. The role of antioxidant compounds from citrus waste in modulating neuroinflammation: a sustainable solution[J]. Antioxidants (Basel), 2025, 14(5): 581.

[37]

Mills SA, Jobling AI, Dixon MA, et al. Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic retinopathy[J/OL]. Proc Natl Acad Sci USA, 2021, 118(51): e2112561118[2025-11-01].

[38]

Yilmaz C, Korovina I, Witt A, et al. Modulation of microglial phagocytosis via the GAS6-MERTK pathway regulates pathological angiogenesis in the mouse oxygen-induced retinopathy model[J]. Cell Death Dis, 2025, 16(1): 428.

[39]

Kim SY, Yoon NG, Im JY, et al. Targeting the mitochondrial chaperone TRAP1 alleviates vascular pathologies in ischemic retinopathy[J/OL]. Adv Sci (Weinh), 2024, 11(2): e2302776[2025-11-01].

[40]

Kumar R, Rottner K, Rao GN. Requirement of site-specific tyrosine phosphorylation of cortactin in retinal neovascularization and vascular leakage[J]. Arterioscler Thromb Vasc Biol, 2024, 44(2): 366-390.

[41]

Jin Y, Zhou X, Chen L, et al. Framework nucleic acids loaded with quercetin: protecting retinal neurovascular unit via the protein kinase B/heme oxygenase-1 pathway[J/OL]. ACS Nano, 2024[2025-11-01].

[42]

Patel NR, K CR, Blanks A, et al. Endothelial cell polarity and extracellular matrix composition require functional ATP6AP2 during developmental and pathological angiogenesis[J/OL]. JCI Insight, 2022, 7(19): e154379[2025-11-01].

[43]

Hombrebueno JR, Lynch A, Byrne EM, et al. Hyaloid vasculature as a major source of STAT3(+) (signal transducer and activator of transcription 3) myeloid cells for pathogenic retinal neovascularization in oxygen-induced retinopathy[J/OL]. Arterioscler Thromb Vasc Biol, 2020, 40(12): e367-e379[2025-11-01].

[44]

Cammalleri M, Amato R, Dal Monte M, et al. The β3 adrenoceptor in proliferative retinopathies: “Cinderella” steps out of its family shadow[J]. Pharmacol Res, 2023, 190: 106713.

[45]

Campochiaro PA, Akhlaq A. Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases[J]. Prog Retin Eye Res, 2021, 83: 100921.

[46]

Tang X, Wang JJ, Wang J, et al. Endothelium-specific deletion of Nox4 delays retinal vascular development and mitigates pathological angiogenesis[J]. Angiogenesis, 2021, 24(2): 363-377.

[47]

Huang SQ, Cao KX, Wang CL, et al. Decreasing mitochondrial fission ameliorates HIF-1α-dependent pathological retinal angiogenesis[J]. Acta Pharmacol Sin, 2024, 45(7): 1438-1450.

[48]

Rezzola S, Loda A, Corsini M, et al. Angiogenesis-inflammation cross talk in diabetic retinopathy: novel insights from the chick embryo chorioallantoic membrane/human vitreous platform[J]. Front Immunol, 2020, 11: 581288.

[49]

Crespo-Garcia S, Tsuruda PR, Dejda A, et al. Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition[J]. Cell Metab, 2021, 33(4): 818-832.

[50]

Jing Y, Zhao W, Zhou Z, et al. Apoptotic vesicles modulate endothelial metabolism and ameliorate ischemic retinopathy via PD1/PDL1 axis[J/OL]. Adv Healthc Mater, 2024, 13(17): e2303527[2025-11-01].

[51]

Liu Z, Xu J, Ma Q, et al. Glycolysis links reciprocal activation of myeloid cells and endothelial cells in the retinal angiogenic niche[J/OL]. Sci Transl Med, 2020, 12(555): eaay1371[2025-11-01].

[52]

Huang YH, Kuo CH, Peng IC, et al. Recombinant thrombomodulin domain 1 rescues pathological angiogenesis by inhibition of HIF-1α-VEGF pathway[J]. Cell Mol Life Sci, 2021, 78(23): 7681-7692.

[53]

Bisen S, Verma SK, Mukhopadhyay CS, et al. A neutrophil elastase-generated mature form of IL-33 is a potent regulator of endothelial cell activation and proliferative retinopathy[J]. Exp Mol Med, 2024, 56(8): 1703-1716.

[54]

Hormel TT, Hwang TS, Bailey ST, et al. Artificial intelligence in OCT angiography[J]. Prog Retin Eye Res, 2021, 85: 100965.

[55]

Hormel TT, Jia Y, Jian Y, et al. Plexus-specific retinal vascular anatomy and pathologies as seen by projection-resolved optical coherence tomographic angiography[J]. Prog Retin Eye Res, 2021, 80: 100878.

[56]

Waheed NK, Rosen RB, Jia Y, et al. Optical coherence tomography angiography in diabetic retinopathy[J]. Prog Retin Eye Res, 2023, 97: 101206.

[57]

Yu C, Dong L, Lv Y, et al. Nanotherapy for neural retinal regeneration[J/OL]. Adv Sci (Weinh), 2025, 12(24): e2409854[2025-11-01].

[58]

Zeng S, Chen Y, Zhou F, et al. Recent advances and prospects for lipid-based nanoparticles as drug carriers in the treatment of human retinal diseases[J]. Adv Drug Deliv Rev, 2023, 199: 114965.

[59]

Cowan CS, Renner M, De Gennaro M, et al. Cell types of the human retina and its organoids at single-cell resolution[J]. Cell, 2020, 182(6): 1623-1640.

[60]

Kurzawa-Akanbi M, Tzoumas N, Corral-Serrano JC, et al. Pluripotent stem cell-derived models of retinal disease: Elucidating pathogenesis, evaluating novel treatments, and estimating toxicity[J]. Prog Retin Eye Res, 2024, 100: 101248.

[61]

Yu J, Yin Y, Leng Y, et al. Emerging strategies of engineering retinal organoids and organoid-on-a-chip in modeling intraocular drug delivery: Current progress and future perspectives[J]. Adv Drug Deliv Rev, 2023, 197: 114842.

[62]

Wang H, Ning X, Zhao F, et al. Human organoids-on-chips for biomedical research and applications[J]. Theranostics, 2024, 14(2): 788-818.

[63]

Quintard C, Tubbs E, Jonsson G, et al. A microfluidic platform integrating functional vascularized organoids-on-chip[J]. Nat Commun, 2024, 15(1): 1452.

[64]

Guo S, Yin S, Tse G, et al. Association between caliber of retinal vessels and cardiovascular disease: a systematic review and Meta-analysis[J]. Curr Atheroscler Rep, 2020, 22(4): 16.

[65]

Zekavat SM, Raghu VK, Trinder M, et al. Deep learning of the retina enables phenome- and genome-wide analyses of the microvasculature[J]. Circulation, 2022, 145(2): 134-150.

[66]

Wang WX, Spiegelman D, Rao PK, et al. Crizanlizumab for retinal vasculopathy with cerebral leukoencephalopathy in a phase II clinical study[J/OL]. J Clin Invest, 2024, 134(24): e189023[2025-11-01].

[67]

Hao J, Kwapong WR, Shen T, et al. Early detection of dementia through retinal imaging and trustworthy AI[J]. NPJ Digit Med, 2024, 7(1): 294.

[68]

Lin R, Zhou Y, Yan T, et al. Directed evolution of adeno-associated virus for efficient gene delivery to microglia[J]. Nat Methods, 2022, 19(8): 976-985.

[69]

Wen Y, Chen X, Feng H, et al. Kdm6a deficiency in microglia/macrophages epigenetically silences Lcn2 expression and reduces photoreceptor dysfunction in diabetic retinopathy[J]. Metabolism, 2022, 136: 155293.

[70]

Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration[J]. Annu Rev Immunol, 2017, 35: 441-468.

[71]

Adrian M, Weber M, Tsai MC, et al. Polarized microtubule remodeling transforms the morphology of reactive microglia and drives cytokine release[J]. Nat Commun, 2023, 14(1): 6322.

[72]

McNamara NB, Munro DAD, Bestard-Cuche N, et al. Microglia regulate central nervous system myelin growth and integrity[J]. Nature, 2023, 613(7942): 120-129.

[73]

Iyer H, Shen K, Meireles AM, et al. A lysosomal regulatory circuit essential for the development and function of microglia[J/OL]. Sci Adv, 2022, 8(35): eabp8321[2025-11-01].

[74]

冯思凡, 李昀峰, 王嘉营, 等. 敲减血红素结合蛋白1基因对小胶质细胞BV2增殖、迁移及炎症反应的影响及其机制[J]. 吉林大学学报(医学版), 2025, 51(6): 1532-1541.

[75]

FENG Sifan, LI Yunfeng, WANG Jiaying, et al. Effects of heme-binding protein 1 gene knockdown on proliferation, migration, and inflammatory response of microglia BV2 and their mechanisms[J]. Journal of Jilin University.Medicine Edition, 2025, 51(6): 1532-1541.

[76]

Yu F, Wang Y, Stetler AR, et al. Phagocytic microglia and macrophages in brain injury and repair[J]. CNS Neurosci Ther, 2022, 28(9): 1279-1293.

[77]

Shemer A, Grozovski J, Tay TL, et al. Engrafted parenchymal brain macrophages differ from microglia in transcriptome, chromatin landscape and response to challenge[J]. Nat Commun, 2018, 9(1): 5206.

[78]

McMenamin PG, Saban DR, Dando SJ. Immune cells in the retina and choroid: Two different tissue environments that require different defenses and surveillance[J]. Prog Retin Eye Res, 2019, 70: 85-98.

[79]

Lier J, Streit WJ, Bechmann I. Beyond activation: characterizing microglial functional phenotypes[J]. Cells, 2021, 10(9): 2236.

[80]

Bennett ML, Bennett FC. The influence of environment and origin on brain resident macrophages and implications for therapy[J]. Nat Neurosci, 2020, 23(2): 157-166.

[81]

Usui-Ouchi A, Giles S, Harkins-Perry S, et al. Integrating human iPSC-derived macrophage progenitors into retinal organoids to generate a mature retinal microglial niche[J]. Glia, 2023, 71(10): 2372-2382.

[82]

Ma X, Wu W, Liang W, et al. Modulation of cGAS-STING signaling by PPARα in a mouse model of ischemia-induced retinopathy[J/OL]. Proc Natl Acad Sci USA, 2022, 119(48): e2208934119[2025-11-01].

[83]

Li H, Li B, Zheng Y. Role of microglia/macrophage polarisation in intraocular diseases (Review)[J]. Int J Mol Med, 2024, 53(5): 45.

[84]

Sato K, Ohno-Oishi M, Yoshida M, et al. The GPR84 molecule is a mediator of a subpopulation of retinal microglia that promote TNF/IL-1α expression via the rho-ROCK pathway after optic nerve injury[J]. Glia, 2023, 71(11): 2609-2622.

[85]

Huang J, Wang X, Li N, et al. YY1 lactylation aggravates autoimmune uveitis by enhancing microglial functions via inflammatory genes[J/OL]. Adv Sci (Weinh), 2024, 11(19): e2308031[2025-11-01].

[86]

He J, Fu Y, Ge L, et al. Disease-associated microglial activation prevents photoreceptor degeneration by suppressing the accumulation of cell debris and neutrophils in degenerating rat retinas[J]. Theranostics, 2022, 12(6): 2687-2706.

[87]

Margeta MA, Yin Z, Madore C, et al. Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma[J]. Immunity, 2022, 55(9): 1627-1644.

[88]

Yu C, Lad EM, Mathew R, et al. Microglia at sites of atrophy restrict the progression of retinal degeneration via galectin-3 and Trem2[J/OL]. J Exp Med, 2024, 221(3): e20231011[2025-11-01].

[89]

Provenzano F, Pérez MJ, Deleidi M. Redefining microglial identity in health and disease at single-cell resolution[J]. Trends Mol Med, 2021, 27(1): 47-59.

[90]

Tezel G. Molecular regulation of neuroinflammation in glaucoma: Current knowledge and the ongoing search for new treatment targets[J]. Prog Retin Eye Res, 2022, 87: 100998.

[91]

Sun Y, Li F, Liu Y, et al. Targeting inflammasomes and pyroptosis in retinal diseases-molecular mechanisms and future perspectives[J]. Prog Retin Eye Res, 2024, 101: 101263.

[92]

Long Y, Li XQ, Deng J, et al. Modulating the polarization phenotype of microglia-A valuable strategy for central nervous system diseases[J]. Ageing Res Rev, 2024, 93: 102160.

[93]

张文娟, 杨林, 张冉. 头蛋白通过STAT3依赖途径的小胶质细胞极化调控和铁稳态重塑缓解神经病理性疼痛[J]. 中南大学学报(医学版), 2025, 50(4): 602-614.

[94]

ZHANG Wenjuan, YANG Lin, ZHANG Ran. Noggin alleviates neuropathic pain by regulating microglial polarization and remodeling iron homeostasis via a STAT3-dependent pathway[J]. Journal of Central South University. Medical Science, 2025, 50(4): 602-614.

[95]

Maurya S, Lin M, Karnam S, et al. Regulation of disease-associated microglia in the optic nerve by lipoxin B(4) and ocular hypertension[J]. Mol Neurodegener, 2024, 19(1): 86.

[96]

Denes V, Lukats A, Szarka G, et al. Long-term effects of the pituitary-adenylate cyclase-activating polypeptide (PACAP38) in the adult mouse retina: microglial activation and induction of neural proliferation[J]. Neurochem Res, 2023, 48(11): 3430-3446.

[97]

Wang Y, Yang X, Zhang Y, et al. Single-cell RNA sequencing reveals roles of unique retinal microglia types in early diabetic retinopathy[J]. Diabetol Metab Syndr, 2024, 16(1): 49.

[98]

Caffarel MM, Braza MS. Microglia and metastases to the central nervous system: victim, ravager, or something else [J]. J Exp Clin Cancer Res, 2022, 41(1): 327.

[99]

Paolicelli RC, Sierra A, Stevens B, et al. Microglia states and nomenclature: A field at its crossroads[J]. Neuron, 2022, 110(21): 3458-3483.

[100]

Wolf J, Boneva S, Rosmus DD, et al. In-depth molecular profiling specifies human retinal microglia identity[J]. Front Immunol, 2022, 13: 863158.

[101]

Bloomfield CL, Gong J, Droho S, et al. Retinal microglia express more MHC class I and promote greater T-cell-driven inflammation than brain microglia[J]. Front Immunol, 2024, 15: 1399989.

[102]

Murenu E, Gerhardt MJ, Biel M, et al. More than meets the eye: The role of microglia in healthy and diseased retina[J]. Front Immunol, 2022, 13: 1006897.

[103]

Hu Z, Mao X, Chen M, et al. Single-cell transcriptomics reveals novel role of microglia in fibrovascular membrane of proliferative diabetic retinopathy[J]. Diabetes, 2022, 71(4): 762-773.

[104]

Xu AH, Yang Y, Shao Y, et al. Poly(ADP-ribose) polymerase family member 14 promotes functional recovery after spinal cord injury through regulating microglia M1/M2 polarization via STAT1/6 pathway[J]. Neural Regen Res, 2023, 18(8): 1809-1817.

[105]

Zhang Y, Chen JC, Zheng JH, et al. Pterosin B improves cognitive dysfunction by promoting microglia M1/M2 polarization through inhibiting Klf5/Parp14 pathway[J]. Phytomedicine, 2024, 135: 156152.

[106]

Li S, Wernersbach I, Harms GS, et al. Microglia subtypes show substrate- and time-dependent phagocytosis preferences and phenotype plasticity[J]. Front Immunol, 2022, 13: 945485.

[107]

Kwon HS, Koh SH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes[J]. Transl Neurodegener, 2020, 9(1): 42.

[108]

Schwabenland M, Brück W, Priller J, et al. Analyzing microglial phenotypes across neuropathologies: a practical guide[J]. Acta Neuropathol, 2021, 142(6): 923-936.

[109]

Gao ML, Zhang X, Han F, et al. Functional microglia derived from human pluripotent stem cells empower retinal organ[J]. Sci China Life Sci, 2022, 65(6): 1057-1071.

[110]

Wang Y, Qin WY, Wang Q, et al. Young Sca-1(+) bone marrow stem cell-derived exosomes preserve visual function via the miR-150-5p/MEKK3/JNK/c-Jun pathway to reduce M1 microglial polarization[J]. J Nanobiotechnology, 2023, 21(1): 194.

[111]

Yu H, Chang Q, Sun T, et al. Metabolic reprogramming and polarization of microglia in Parkinson’s disease: Role of inflammasome and iron[J]. Ageing Res Rev, 2023, 90: 102032.

[112]

Huang K, Lin Z, Ge Y, et al. Immunomodulation of MiRNA-223-based nanoplatform for targeted therapy in retinopathy of prematurity[J]. J Control Release, 2022, 350: 789-802.

[113]

Liu Y, Xia P, Yan F, et al. Engineered extracellular vesicles for delivery of an IL-1 Receptor antagonist promote targeted repair of retinal degeneration[J/OL]. Small, 2023, 19(46): e2302962[2025-11-01].

[114]

Li Y, Teng X, Yang C, et al. Ultrasound controlled anti-inflammatory polarization of platelet decorated microglia for targeted ischemic stroke therapy[J]. Angew Chem Int Ed Engl, 2021, 60(10): 5083-5090.

[115]

Chong L, Jiang YW, Wang D, et al. Targeting and repolarizing M2-like tumor-associated macrophage-mediated MR imaging and tumor immunotherapy by biomimetic nanoparticles[J]. J Nanobiotechnology, 2023, 21(1): 401.

[116]

Zeng HX, Qin SJ, Wu QZ, et al. Circular RNA circ_0061183 regulates microglial polarization induced by airborne ultrafine particles in HMC3 cells via sponging miR-98-5p[J]. J Hazard Mater, 2025, 484: 136719.

[117]

Sabogal-Guaqueta AM, Marmolejo-Garza A, Trombetta-Lima M, et al. Species-specific metabolic reprogramming in human and mouse microglia during inflammatory pathway induction[J]. Nat Commun, 2023, 14(1): 6454.

[118]

Zhong X, Gong S, Meng L, et al. Cordycepin modulates microglial M2 polarization coupled with mitochondrial metabolic reprogramming by targeting HKII and PDK2[J/OL]. Adv Sci (Weinh), 2024, 11(31): e2304687[2025-11-01].

[119]

Caruso SM, Ryu J, Quinn PM, et al. Precision metabolome reprogramming for imprecision therapeutics in retinitis pigmentosa[J]. J Clin Invest, 2020, 130(8): 3971-3973.

[120]

Chen R, Zheng S, Zhao X, et al. Metabolic reprogramming of macrophages by a nano-sized opsonization strategy to restore M1/M2 balance for osteoarthritis therapy[J]. J Control Release, 2025, 380: 469-489.

[121]

Peng S, Chen Y, Wang R, et al. Z-ligustilide provides a neuroprotective effect by regulating the phenotypic polarization of microglia via activating Nrf2-TrxR axis in the Parkinson’s disease mouse model[J]. Redox Biol, 2024, 76: 103324.

[122]

Procès A, Alpizar YA, Halliez S, et al. Stretch-injury promotes microglia activation with enhanced phagocytic and synaptic stripping activities[J]. Biomaterials, 2024, 305: 122426.

[123]

Jäckle K, Zeis T, Schaeren-Wiemers N, et al. Molecular signature of slowly expanding lesions in progressive multiple sclerosis[J]. Brain, 2020, 143(7): 2073-2088.

[124]

Alsoudi AF, Wai KM, Koo E, et al. Progression to pars plana vitrectomy in patients with proliferative diabetic retinopathy[J]. JAMA Ophthalmol, 2024, 142(7): 662-668.

[125]

Tao W, Zhang G, Liu C, et al. Low-dose LPS alleviates early brain injury after SAH by modulating microglial M1/M2 polarization via USP19/FOXO1/IL-10/IL-10R1 signaling[J]. Redox Biol, 2023, 66: 102863.

[126]

Jin L, Zhu Z, Hong L, et al. ROS-responsive 18β-glycyrrhetic acid-conjugated polymeric nanoparticles mediate neuroprotection in ischemic stroke through HMGB1 inhibition and microglia polarization regulation[J]. Bioact Mater, 2023, 19: 38-49.

[127]

Lu Y, Zhou M, Li Y, et al. Minocycline promotes functional recovery in ischemic stroke by modulating microglia polarization through STAT1/STAT6 pathways[J]. Biochem Pharmacol, 2021, 186: 114464.

[128]

Petry P, Oschwald A, Merkt S, et al. Early microglia progenitors colonize the embryonic CNS via integrin-mediated migration from the pial surface[J]. Dev Cell, 2026, 61(1): 85-101.

[129]

Yoshizaki S, Tamaru T, Hara M, et al. Microglial inflammation after chronic spinal cord injury is enhanced by reactive astrocytes via the fibronectin/β1 integrin pathway[J]. J Neuroinflammation, 2021, 18(1): 12.

[130]

Xie X, Liu X, Zhu J, et al. Long-term microglial phase-specific dynamics during single vessel occlusion and recanalization[J]. Commun Biol, 2022, 5(1): 841.

[131]

Martínez IZ, Pérez-Martínez C, Salinas LM, et al. Phenotypic characterization of encephalitis and immune response in the brains of lambs experimentally infected with Spanish goat encephalitis virus[J]. Animals (Basel), 2020, 10(8): 1373.

[132]

Xie H, Zhang C, Liu D, et al. Erythropoietin protects the inner blood-retinal barrier by inhibiting microglia phagocytosis via Src/Akt/cofilin signalling in experimental diabetic retinopathy[J]. Diabetologia, 2021, 64(1): 211-225.

[133]

Zhou L, Xu Z, Oh Y, et al. Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy[J/OL]. JCI Insight, 2021, 6(23): e93382[2025-11-01].

[134]

Kinuthia UM, Moehle C, Adams RH, et al. Immunomodulation of inflammatory responses preserves retinal integrity in murine models of pericyte-depletion retinopathy[J/OL]. JCI Insight, 2025, 10(15): e184465[2025-11-01].

[135]

Fletcher EL, Dixon MA, Mills SA, et al. Anomalies in neurovascular coupling during early diabetes: A review[J]. Clin Exp Ophthalmol, 2023, 51(1): 81-91.

[136]

Dixon MA, Greferath U, Fletcher EL, et al. The contribution of microglia to the development and maturation of the visual system[J]. Front Cell Neurosci, 2021, 15: 659843.

[137]

Lee SJ, Noh SE, Jo DH, et al. IL-10-induced modulation of macrophage polarization suppresses outer-blood-retinal barrier disruption in the streptozotocin-induced early diabetic retinopathy mouse model[J]. FASEB J, 2024, 38(9): e23638[2026-02-01].

[138]

Avramovic D, Archaimbault SA, Kemble AM, et al. TGFβ1 induces senescence and attenuated VEGF production in retinal pericytes[J]. Biomedicines, 2022, 10(6): 1404.

[139]

Dharmarajan S, Carrillo C, Qi Z, et al. Retinal inflammation in murine models of type 1 and type 2 diabetes with diabetic retinopathy[J]. Diabetologia, 2023, 66(11): 2170-2185.

[140]

Fu X, Feng S, Qin H, et al. Microglia: The breakthrough to treat neovascularization and repair blood-retinal barrier in retinopathy[J]. Front Mol Neurosci, 2023, 16: 1100254.

[141]

Shestopalov VI, Spurlock M, Gramlich OW, et al. Immune responses in the glaucomatous retina: regulation and dynamics[J]. Cells, 2021, 10(8): 1973.

[142]

Lu T, Shang J, Pu S, et al. The role of microglia in the development of diabetic retinopathy and its potential clinical application[J]. Hum Cell, 2025, 38(4): 101.

[143]

Grimes WN, Berson DM, Sabnis A, et al. Layer-specific anatomical and physiological features of the retina’s neurovascular unit[J]. Curr Biol, 2025, 35(1): 109-120.

[144]

Rowthorn-Apel N, Vridhachalam N, Connor KM, et al. Microglial depletion decreases Muller cell maturation and inner retinal vascular density[J]. Cell Commun Signal, 2025, 23(1): 90.

[145]

Császár E, Lénárt N, Cserép C, et al. Microglia modulate blood flow, neurovascular coupling, and hypoperfusion via purinergic actions[J/OL]. J Exp Med, 2022, 219(3): e20211071[2025-11-01].

[146]

Liu Z, Shi H, Xu J, et al. Single-cell transcriptome analyses reveal microglia types associated with proliferative retinopathy[J/OL]. JCI Insight, 2022, 7(23): e160940[2025-11-01].

[147]

Chen L, Cao Y, Shen Y, et al. Downregulation of PIK3IP1 in retinal microglia promotes retinal pathological neovascularization via PI3K-AKT pathway activation[J]. Sci Rep, 2023, 13(1): 12754.

[148]

Dejda A, Mawambo G, Daudelin JF, et al. Neuropilin-1-expressing microglia are associated with nascent retinal vasculature yet dispensable for developmental angiogenesis[J]. Invest Ophthalmol Vis Sci, 2016, 57(4): 1530-1536.

[149]

Phipps JA, Vessey KA, Brandli A, et al. The role of angiotensin II/AT1 receptor signaling in regulating retinal microglial activation[J]. Invest Ophthalmol Vis Sci, 2018, 59(1): 487-498.

[150]

He C, Liu Y, Huang Z, et al. A specific RIP3(+) subpopulation of microglia promotes retinopathy through a hypoxia-triggered necroptotic mechanism[J/OL]. Proc Natl Acad Sci USA, 2021, 118(11): e2023290118[2025-11-01].

[151]

Huang Z, Zhou T, Sun X, et al. Necroptosis in microglia contributes to neuroinflammation and retinal degeneration through TLR4 activation[J]. Cell Death Differ, 2018, 25(1): 180-189.

[152]

Losenkova K, Takeda A, Ragauskas S, et al. CD73 controls ocular adenosine levels and protects retina from light-induced phototoxicity[J]. Cell Mol Life Sci, 2022, 79(3): 152.

[153]

Huang Z, Liang J, Chen S, et al. RIP3-mediated microglial necroptosis promotes neuroinflammation and neurodegeneration in the early stages of diabetic retinopathy[J]. Cell Death Dis, 2023, 14(3): 227.

[154]

Ting KK, Zhao Y, Shen W, et al. Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models[J]. Diabetologia, 2019, 62(2): 322-334.

[155]

Chang W, Lv X, Zhu J, et al. Multifunctional nanotherapeutics with long-acting release against macular degeneration by minimally invasive administration[J/OL]. ACS Nano, 2024[2025-11-01].

[156]

Yang X, Diaz V, Huang H. The role of Interferon Regulatory Factor 1 in regulating microglial activation and retinal inflammation[J]. Int J Mol Sci, 2022, 23(23): 14664.

[157]

Xue B, Ge M, Fan K, et al. Mitochondria-targeted nanozymes eliminate oxidative damage in retinal neovascularization disease[J]. J Control Release, 2022, 350: 271-283.

[158]

Bohley M, Dillinger AE, Schweda F, et al. A single intravenous injection of cyclosporin A-loaded lipid nanocapsules prevents retinopathy of prematurity[J/OL]. Sci Adv, 2022, 8(38): eabo6638[2025-11-01].

[159]

Zhao H, Wu L, Yan G, et al. Inflammation and tumor progression: signaling pathways and targeted intervention[J]. Signal Transduct Target Ther, 2021, 6(1): 263.

[160]

Liu X, Zeng S, Meng J, et al. BARD1-mediated stabilization of METTL14 promotes retinal neovascularization by m6A-modifying MXD1 mRNA on a YTHDF2-dependent manner[J]. Theranostics, 2025, 15(11): 5481-5498.

[161]

Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, et al. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin[J]. Med Res Rev, 2023, 43(5): 1668-1700.

[162]

Reyes NJ, O’Koren EG, Saban DR. New insights into mononuclear phagocyte biology from the visual system[J]. Nat Rev Immunol, 2017, 17(5): 322-332.

[163]

Sharma A, Porterfield JE, Smith E, et al. Effect of mannose targeting of hydroxyl PAMAM dendrimers on cellular and organ biodistribution in a neonatal brain injury model[J]. J Control Release, 2018, 283: 175-189.

[164]

Mathew B, Ravindran S, Liu X, et al. Mesenchymal stem cell-derived extracellular vesicles and retinal ischemia-reperfusion[J]. Biomaterials, 2019, 197: 146-160.

[165]

Cao F, Liang K, Tang WW, et al. Polyvinylpyrrolidone-curcumin nanoparticles with immune regulatory and metabolism regulatory effects for the treatment of experimental autoimmune uveitis[J]. J Control Release, 2024, 372: 551-570.

[166]

Qian C, Xin Y, Qi C, et al. Intercellular communication atlas reveals Oprm1 as a neuroprotective factor for retinal ganglion cells[J]. Nat Commun, 2024, 15(1): 2206.

[167]

Cameron EG, Nahmou M, Toth AB, et al. A molecular switch for neuroprotective astrocyte reactivity[J]. Nature, 2024, 626(7999): 574-582.

[168]

Wang M, Wang M, Dong C, et al. Hesperidin-loaded nanoparticles attenuate pathological angiogenesis in oxygen-induced retinopathy by modulating the retinal immune microenvironment[J]. ACS Biomater Sci Eng, 2026, 12(3): 1826-1847.

基金资助

RIGHTS & PERMISSIONS

©Journal of Central South University (Medical Science). All rights reserved.

AI Summary AI Mindmap
PDF (2384KB)

423

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉